YZYuan-Yuan Zhang

Yuan-Yuan Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yuan-Yuan Zhang has a total of 4 co-authors. Here are the top co-authors by number of shared publications:

  • En-Qiang Chen

    Center of Infectious Diseases, West China Hospital of Sichuan University

    1 shared publication
  • Hong Tang

    Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu 610041, China

    1 shared publication
  • Jin Yang

    Department of Infectious Diseases, the Affiliated Shenzhen Nanshan Hospital of Guangdong Medical College, No 89, Taoyuan Road, Nanshan district, 518052 Shenzhen, China

    1 shared publication
  • Yu-Rong Duan

    The Chinese Cochrane Center/the Chinese Evidence- Based Medicine Center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, PR China

    1 shared publication

Latest Publications

  • Open Access

    Treatment with lamivudine versus lamivudine and thymosin alpha-1 for e antigen-positive chronic hepatitis B patients: a meta-analysis

    by Yuan-Yuan Zhang, En-Qiang Chen, Jin Yang, Yu-Rong Duan, Hong Tang

    Background: Currently, there is no evidence on the combination of lamivudine and thymosin alpha-1 on chronic hepatitis B patients. The aim of this study was to compare the effect of lamivudine monotherapy with that of lamivudine and thymosin alpha-1 combination therapy for the treatment of hepatitis B e antigen (HBeAg)-positive hepatitis B patients. Results: We searched PUBMED (from 1966 onwards), EMBASE (from 1966), CBMdisk (Chinese Biomedical Database, from 1978), CNKI (National Knowledge Infrastructure, from 1980), the Cochrane Central Register of Controlled Trials and the Cochrane Database of Systematic Reviews. Eight trials (583 patients in total) were identified. The lamivudine and thymosin alpha-1 combination treatment was significantly superior to lamivudine treatment in terms of ALT normalization rate (80.2% vs. 68.8%, P = 0.01), virological response rate (84.7% vs. 74.9%, P = 0.002), and HBeAg seroconversion rate (45.1% vs. 15.2%, P < 0.00001). Conclusion: Among HBeAg-positive patients, thymosin alpha-1 and lamivudine combination therapy may be more effective than lamivudine monotherapy, providing superior rates of biochemical response, virological response, and HBeAg seroconversion.